Comments on: Tysabri’s Tally of PML Cases Reaches 13 http://www.xconomy.com/boston/2009/09/17/tysabris-tally-of-pml-cases-reaches-13/ Business + Technology in the Exponential Economy Sat, 11 Feb 2012 01:39:24 +0000 hourly 1 http://wordpress.org/?v=3.0.4 By: Kristy Kilpin http://www.xconomy.com/boston/2009/09/17/tysabris-tally-of-pml-cases-reaches-13/comment-page-1/#comment-83829 Kristy Kilpin Mon, 28 Sep 2009 14:38:11 +0000 http://www.xconomy.com/?p=41985#comment-83829 In response to Luke Timmerman's recent report on natalizumab (Tysabri)connection to 13 cases of a potentially fatal brain infection, I thought there might be interest for interested communities to attend this upcoming event in New York City on November 10th: Tuesday, November 10, 2009 (8:00am-5:30pm) Immunomodulating Therapies and Progressive Multifocal Leukoencephalopathy (PML) The aim of this symposium is to provide a forum to discuss whether Progressive multifocal leukoencephalopathy (PML) that has been seen in multiple drug trails is a direct consequence of the mechanism of therapeutic action or whether it’s an off-target adverse affect of the therapeutic agent. www.nyas.org/PML. Sponsored by the New York Academy of Sciences. In response to Luke Timmerman’s recent report on natalizumab (Tysabri)connection to 13 cases of a potentially fatal brain infection, I thought there might be interest for interested communities to attend this upcoming event in New York City on November 10th:

Tuesday, November 10, 2009 (8:00am-5:30pm)
Immunomodulating Therapies and Progressive Multifocal Leukoencephalopathy (PML)

The aim of this symposium is to provide a forum to discuss whether Progressive multifocal leukoencephalopathy (PML) that has been seen in multiple drug trails is a direct consequence of the mechanism of therapeutic action or whether it’s an off-target adverse affect of the therapeutic agent. http://www.nyas.org/PML. Sponsored by the New York Academy of Sciences.

]]>